Raymond R Townsend1, Paul A Sobotka2,3. 1. Perelman School of Medicine, Renal, Electrolyte and Hypertension Division, University of Pennsylvania, 122 Founders Building, 3400 Spruce Street, Philadelphia, PA, 19104, USA. townsend@upenn.edu. 2. The Ohio State, Columbus, OH, USA. 3. Chief Medical Officer, Rox Medical, Inc., San Clemente, CA, USA.
Abstract
PURPOSE OF REVIEW: This review was undertaken to update readers on the field of therapeutic renal denervation for hypertension during the 2016 through 2018 period. RECENT FINDINGS: After the failure of Symplicity HTN-3 to meet its top line objective, intense scrutiny revealed several possible concerns addressed by the newer investigations into the area of renal denervation. These included better device technology, more intense subject monitoring for off-protocol antihypertensive drug usage, and deeper penetration into the renal vasculature by the interventionist. Whether untreated by medication for hypertension or on antihypertensive medication, renal denervation shows a clear, though moderate, blood pressure reduction. The failure of roughly one out of three patients with hypertension to respond to denervation procedures argues that there is room for improvement in choosing the optimal patient for this approach to hypertension management.
PURPOSE OF REVIEW: This review was undertaken to update readers on the field of therapeutic renal denervation for hypertension during the 2016 through 2018 period. RECENT FINDINGS: After the failure of Symplicity HTN-3 to meet its top line objective, intense scrutiny revealed several possible concerns addressed by the newer investigations into the area of renal denervation. These included better device technology, more intense subject monitoring for off-protocol antihypertensive drug usage, and deeper penetration into the renal vasculature by the interventionist. Whether untreated by medication for hypertension or on antihypertensive medication, renal denervation shows a clear, though moderate, blood pressure reduction. The failure of roughly one out of three patients with hypertension to respond to denervation procedures argues that there is room for improvement in choosing the optimal patient for this approach to hypertension management.
Authors: Marat Fudim; Asher A Sobotka; Yue-Hui Yin; Joanne W Wang; Howard Levin; Murray Esler; Jie Wang; Paul A Sobotka Journal: Curr Hypertens Rep Date: 2018-05-01 Impact factor: 5.369
Authors: Elżbieta Florczak; Bogdan Tokarczyk; Ewa Warchoł-Celińska; Elżbieta Szwench-Pietrasz; Aleksander Prejbisz; Maria Gosk; Marek Kabat; Krzysztof Narkiewicz; Andrzej Januszewicz; Maria Kała Journal: Pol Arch Med Wewn Date: 2015-01-12
Authors: Ulla C Kopp; Michael Z Cicha; Lori A Smith; Jan Mulder; Tomas Hökfelt Journal: Am J Physiol Regul Integr Comp Physiol Date: 2007-08-15 Impact factor: 3.619
Authors: Felix Mahfoud; George Bakris; Deepak L Bhatt; Murray Esler; Sebastian Ewen; Martin Fahy; David Kandzari; Kazuomi Kario; Giuseppe Mancia; Michael Weber; Michael Böhm Journal: Eur Heart J Date: 2017-01-07 Impact factor: 29.983
Authors: Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler Journal: Lancet Date: 2009-03-28 Impact factor: 79.321
Authors: Raymond R Townsend; Felix Mahfoud; David E Kandzari; Kazuomi Kario; Stuart Pocock; Michael A Weber; Sebastian Ewen; Konstantinos Tsioufis; Dimitrios Tousoulis; Andrew S P Sharp; Anthony F Watkinson; Roland E Schmieder; Axel Schmid; James W Choi; Cara East; Anthony Walton; Ingrid Hopper; Debbie L Cohen; Robert Wilensky; David P Lee; Adrian Ma; Chandan M Devireddy; Janice P Lea; Philipp C Lurz; Karl Fengler; Justin Davies; Neil Chapman; Sidney A Cohen; Vanessa DeBruin; Martin Fahy; Denise E Jones; Martin Rothman; Michael Böhm Journal: Lancet Date: 2017-08-28 Impact factor: 79.321